Opiant Pharmaceuticals — Investor Presentation (April 2017)
34 slides from Opiant Pharmaceuticals's investor presentation, Apr 19, 2017
Slide 1: Focused on Addiction
FOCUSED ON ADDICTION Investor Presentation April 2017 OTCQB: OPNT
Slide 2: Forward Looking Statement
Forward Looking Statement 2 This presentation contains ‘forward - looking statements’ within the meaning of Section of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934 as amended. These forward - looking statements relate to future events or our future fi
Slide 3: OPNT: Focused on Addiction
3 OPNT: Focused on Addiction A Commercial - Stage Specialty Pharma Company Focused on Addiction Leveraging expertise, technology and a record of success to address the leading sources of addiction • Opioids • Alcohol • Food
Slide 4: Lead Programs
4 Lead Programs Indication Product Candidate / Regulatory Pathway Preclinical Phase 1 Phase II Phase III NDA FDA Approval Partner Opioid Overdose NARCAN® Nasal Spray 505(b)(2) Alcohol Dependence OPNT002 Opioid Antagonist Nasal Spray / 505(b)(2) Eating Disorders OPNT001 Opioid Antagonist Nasal Spray
Slide 5: Management team
Arvind Agrawal MSc EVP, Medical Affairs Extensive addiction and CNS drug development experience 5 Dr. Roger Crystal MD MRCS MBA Chief Executive Officer Kevin Pollack, JD MBA Chief Financial Officer Mark Ellison, Ph.D. EVP Development, Manufacturing and Quality Dr. Phil Skolnick Ph.D D.Sc hon
Slide 6: Opiant's mission: leading biopharma focused on addictions and eating disorders
Opiant’s mission: to become a leading biopharma focused on addictions and eating disorders Replicate recent success Enter Larger Markets Invest long term Deliver on first program • Deliver more programs, with the potential for filing NDAs within 3 - 4 years at relatively low cost, primarily using na
Slide 7: Addressing Addiction
Addressing Addiction @ Opiant
Slide 8: Addiction has evolved as a disease, now more acceptable to treat with pharmacotherapy
8 Addiction has evolved as a disease, and now more acceptable to treat with pharmacotherapy The Past: Addicts as “junkies”; abstinence the only solution The Present: Addiction now recognized as a brain disease; abstinence no longer viewed as the only acceptable outcome The Future: Promising pharmaco
Slide 9: Addiction now represents an attractive commercial opportunity
Addiction now represents an attractive commercial opportunity 9 Strong sales from existing products • Suboxone sales > $1B • 27% growth in Vivitrol sales expected for 2017 - $250M Significant unmet need & increased government funding • Only 1 in 9 addicts receive appropriate treatment • Problem grow
Slide 10: Addictions driven by the brain's reward center, blocked by opioid antagonists
10 Addictions are driven by the brain’s reward center releasing dopamine which can be blocked by opioid antagonists • Dopamine controls the brain’s reward and pleasure centers • Opioids flood the brain with dopamine, leading to misuse and abuse The Addicted Brain • Opioid antagonists bind to opiate
Slide 11: OPNT001 displaces carfentanyl from the brain's breathing and reward centers
Opiant’s OPNT001 opioid antagonist displaces the opioid carfentanyl from the brain’s breathing and reward centers 11 Prior to OPNT001 2 time points after administration of OPNT001
Slide 12: Opioid antagonists validated as therapeutics with excellent safety profile
12 Opioid antagonists have been validated as therapeutics with an excellent safety profile
Slide 13: NARCAN Nasal Spray
NARCAN® Nasal Spray @ Opiant pe 13
Slide 14: Opioid addiction and overdose: a significant public health crisis
14 Opioid addiction and overdose: A significant public health crisis Source: Centers for Disease Control and Prevention • Opioid overdose deaths have increased dramatically since 2000 • The majority of opioid overdose deaths are accidental following legitimate use • Approximately 33,000 overdose dea
Slide 15: Naloxone saves lives if given quickly
15 Naloxone saves lives if given quickly However: only trained personnel able to deliver injectable form, which delays lifesaving treatment Timing is Everything: Understanding the Urgency to Respond Quickly Dial 911 Await ambulance Patient already stopped breathing Help often arrives too late Opioid
Slide 16: NARCAN Nasal Spray is the only FDA-approved nasal naloxone
16 NARCAN® Nasal Spray is the only FDA - approved nasal naloxone for reversal of opioid overdose • Developed by Opiant • 2 doses now FDA approved, 2mg and 4mg • Higher dose increasingly important for overdose caused by fentanyl and other synthetics • Licensed to Adapt Pharma in 2014 for $55+ million
Slide 17: NARCAN Nasal Spray: rapid absorption with higher blood levels
17 NARCAN® Nasal Spray: Rapid absorption with higher blood levels compared to 0.4mg injectable naloxone Time Post Administration (hour) Naloxone Concentration (ng/ml) Dose 3 – 0.4mg Intramuscular Dose 1 – 4mg Intranasal Dose 2 – 2mg Intranasal 6.0 5.0 4.0 3.0 2.0 1.0 0.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0
Slide 18: NARCAN Nasal Spray: easiest to use, needle free, among the least expensive
18 NARCAN® Nasal Spray – Easiest to use, needle free and among the least expensive Injectable Naloxone Autoinjectors Improvised Nasal Kits NARCAN® Nasal Spray • Only suitable for trained personnel • Requires prep time • Requires a needle • Expensive • Not needle free - requires an injection • Only s
Slide 19: Potential $2B addressable market in U.S.
19 Over 20 million unique opioid users resulting in a potential $2B addressable market in U.S. *Opiant estimate of average selling price ** Co - prescribing starting to happen – mandatory in Vermont for high risk patients First Responders 1M patients with opioid use disorder taking methadone, suboxo
Slide 20: Beyond Overdose: Addressing Chronic Treatment of Addictions
Beyond Overdose … .Addressing Chronic Treatment of Addictions 20
Slide 21: Leveraging NARCAN success to address larger, broader addiction markets
Opiant is leveraging NARCAN® success to address larger, broader addiction markets 12M 1.5M Opioid Overdose ~33k deaths per year Alcohol Use Disorder ~17 million Eating Disorders ~20 million Opioid Use Disorder ~2.4 million ACUTE CHRONIC 21
Slide 22: Alcohol Use Disorder: 500k patients prescribed ~$360M of mostly generic medication
Alcohol Use Disorder (AUD): 500k patients prescribed ~$360M of mostly generic medication at treatment centers 22 • Of the 17M patients that meet the diagnostic criteria for an AUD, only 500k patients receive mostly generic pharmacotherapy, mostly at dedicated treatment centers • Approximately $360M
Slide 23: Existing pharmacotherapies for Alcohol Use Disorder have limitations
23 OPNT Existing Pharmacotherapies Criteria OPNT002 * Acamprosate Disulfiram Naltrexone HCl (Oral: ReVia ® / Generics) Naltrexone HCl (Injection: Vivitrol ®) “As - needed” use basis ✔ ✘ ✘ Can be used this way, but not current US practice ✘ Well - tolerated ✔ ✔ ✘ ✘ ✔ Safety ✔ − − ✔ ✔ Craving impact p
Slide 24: OPNT002 will be a differentiated product
Combining targeted dosing with a harm reduction endpoint, OPNT002 will be a differentiated product 24 • Patients will take the nasal spray when they have the urge to drink • Attractive, targeted “as needed” dosing approach – improved tolerability, compliance and patient acceptability over daily dosi
Slide 25: FDA feedback supportive of OPNT002 development plan
25 FDA feedback supportive of OPNT002 development plan alongside attractive commercial opportunity • Phase 1 data highly encouraging • Further clinical studies planned for 2H 2017 • 505(b)(2) regulatory pathway confirmed – increased likelihood and speed for FDA approval • Potential to self - commerc
Slide 26: OPNT001 for Eating Disorders
OPNT001 for Eating Disorders 26
Slide 27: Eating disorders affect millions with only one drug approved in each indication
Eating disorders affect millions with only one drug approved in each indication 27 Bulimia Nervosa • Bingeing and purging • Severe complications if untreated • Compulsive bingeing has features in common with addictions • Fluoxetine only approved drug Binge Eating Disorder • Most common eating disord
Slide 28: OPNT001 Phase 2 trial design for Bulimia Nervosa
OPNT001 Phase 2 trial design for Bulimia Nervosa 28 • Randomized, double blind, placebo controlled study of 4mg IN OPNT001 in patients suffering from Bulimia Nervosa in the UK • 80 patients • Primary endpoint – reduction in binge eating days • Expected duration – 12 months (further guidance once pat
Slide 29: OPNT001 shows promise for Binge Eating Disorder
164.8 171.3 174.8 179.9 188.6 199.9 0 - 40 - 80 - 120 - 160 - 180 Base 1 - 20 - 60 - 100 - 140 2 3 4 5 6 OPNT001 shows promise for Binge Eating Disorder 29 Proof of concept study (Helsinki) • (n=127) in patients with BED, Randomized, double blind, placebo controlled study • OPNT001 dose 2mg before e
Slide 30: Corporate
Corporate @ Opiant pe 30
Slide 31: Extensive IP coverage
31 Extensive IP coverage: Four Orange Book listed patents and several more IP filings across many indications Co - Packaging/Co - Provision Spray Plume Geometry Single Pre - Primed Device Formulation & Dose PET Data Receptor Occupancy Clinical Data Absorption Blood PK Data Methods Treat Overdose
Slide 32: Corporate/Clinical Milestones
32 Corporate/Clinical Milestones Enhance corporate governance through establishment of Board committees (1Q 2017) Initiate of Phase 2 trial of OPNT001 in Bulimia Nervosa (2Q 2017) Uplist to a major stock exchange Strengthen management team through appointment of a CSO (1Q 2017) Initiate OPNT 002 Alc
Slide 33: OPNT: Investment Highlights
33 OPNT: Investment Highlights Record of commercialization in addiction, where others have failed High value pipeline, clinical and regulatory success in developing nasally - delivered opioid antagonists Significant competitive advantages and strong IP Strong partnerships and strengthened balance sh
Slide 34: Focused on Addiction
FOCUSED ON ADDICTION www.opiant.com
Opiant Pharmaceuticals — Investor Presentation (April 2017) on 6ix